Phase I Study of68Ga-NOTA-HL for PET/CT Imaging of Hepatic Asialoglycoprotein Receptors in Healthy Volunteers
Journal
Journal of Nuclear Medicine Technology
Journal Volume
53
Journal Issue
2
Start Page
152-157
ISSN
0091-4916
1535-5675
Date Issued
2025-05-09
Author(s)
Abstract
This study investigated the safety, biodistribution, and dosimetry of 68Ga-hexavalent lactoside (68Ga-NOTA-HL), a PET tracer targeting asialoglycoprotein receptors (ASGPRs) on hepatocytes. ASGPRs, key for glycoprotein homeostasis, serve as a valuable biomarker of liver function. 68Ga-NOTA-HL demonstrated excellent safety in 12 healthy volunteers with no adverse events. Biodistribution studies revealed high liver uptake with minimal uptake in other organs, consistent with ASGPR targeting. The effective dose was 0.0289 mSv/MBq, indicating low radiation exposure. These findings suggest 68Ga-NOTA-HL PET/CT holds significant promise as a safe and effective imaging technique for assessing liver function. The high liver specificity and extremely low background activity provide a strong foundation for further clinical investigations into its potential for evaluating liver function in various clinical settings, including the assessment of liver reserve in patients with liver diseases.
Subjects
68Ga-NOTA-HL
PET/CT
asialoglycoprotein receptors
biodistribution
dosimetry
liver functional reserve
safety
Publisher
Society of Nuclear Medicine
Type
journal article